Context: There are interplays between the endocrine and exocrine pancreas. We recently reported an increased frequency of exocrine dysfunction in HNF1A-maturity-onset diabetes of the young (MODY3) patients, compared with controls. Reduced pancreatic volume is seen in HNF1B-MODY (MODY5) and diabetes types 1 and 2.
T
here is an exocrine component in several forms of monogenic diabetes. In maturity-onset diabetes of the young (MODY) due to mutations in HNF1B (HNF1B-MODY, MODY5), pancreatic atrophy is a common feature (1, 2) and most likely caused by a developmental defect (3) . Moreover, we have described pancreatic atrophy and lipomatosis in subjects with diabetes and pancreatic exocrine dysfunction caused by mutations in the carboxyl-ester lipase (CEL) gene (4, 5) , suggesting that fatty replacement could reflect a process involved in pancreatic disease development in this MODY subtype. Interestingly, radiological studies have reported reduced pancreatic volume in patients with type 1 diabetes and to some degree in patients with insulindependent type 2 diabetes (6 -8) . The pancreatic size reduction in type 1 and 2 diabetes may be secondary to a reduced insulinotropic effect on the acinar cells (9 -11) . A correlation between the pancreatic volume and pancreatic exocrine function measured by serum immunoreactive trypsin has also been reported (6) .
We recently found that 13% of adult HNF1A mutation carriers have pancreatic exocrine dysfunction (12) . HNF1A is closely related to HNF1B. Hence, morphological changes sim-ilar to those reported for HNF1B-MODY might be suspected. We therefore aimed to study pancreatic structure and its relation to exocrine function in HNF1A-MODY and to make a comparison with type 1 and type 2 diabetes subjects as well as normal controls.
Subjects and Methods

Subjects
We invited all adult HNF1A mutation carriers in the Norwegian MODY Registry and subjects with types 1 and 2 diabetes recruited consecutively from an outpatient diabetes clinic to test for pancreatic exocrine dysfunction. The clinical characteristics of the study subjects are described in Table 1 . Subjects diagnosed with exocrine dysfunction, were compared with subjects of the same diabetes subtype but with normal exocrine function. There was no significant difference in age, age at examination, body mass index (BMI) or body surface area between the groups. All subjects were investigated with computed tomography (CT) of the pancreas by a standardized protocol. From a CT archive, we included controls without known diabetes or pancreatic disease that were matched for age, sex, and body surface area.
The study was approved by the Regional Committee for Research Ethics and the Norwegian Data Inspectorate and performed according to the Helsinki Declaration. We obtained written informed consent from all participants.
Measurement of pancreatic volume and x-ray attenuation
For the radiological study, helical CT (Light Speed Ultra; GE, Milwaukee, WI) of the pancreas (5 mm collimation, 5 mm reconstruction increment) was performed with and without contrast. Some examinations performed at local hospitals had slightly modified scan parameters. A radiologist (I.S.H.) traced the contour of the pancreas on contrast series on every slice to estimate the pancreatic volume as previously described (4) Pancreatic attenuation on contrast series in the encircled areas were used to calculate average x-ray attenuation measured in Hounsfield Units (HU; values equaling Ϫ1000 in air, Ϫ100 in fat, 0 in water, and ϩ1000 in bone). To control for the influence of body build on pancreatic volume, the pancreatic volume index was calculated by dividing pancreatic volume by body surface area (6) as calculated by the formula of DuBois (13) .
Definition of pancreatic exocrine dysfunction
Fecal elastase-1 was determined by ELISA using a kit specific for human elastase-1 (ScheBo-Tech GmbH, Wettenberg-Giessen, Germany). Pancreatic exocrine dysfunction was defined as fecal elastase deficiency, i.e. fecal elastase levels less than 200 g/g in two consecutive tests. Seventytwo-hour stool samples were collected as previously described (12),and fecal fat was quantified according to van de Kamer et al. (14) , considering 7 g or less of fat per 24 h normal.
Statistics
Results for continuous variables are given as mean (SD). We used one-way ANOVA for global assessment and two-tailed, unpaired Student's t tests in the subgroup analyses for comparison of clinical characteristics and for comparison of pancreatic volume index and x-ray attenuation between HNF1A mutation carriers and each control group. We chose a significance level of 5% but 1% in the case of multiple testing. Associations between pancreatic volume index and attenuation, respectively, with age, BMI, duration of diabetes, fecal elastase level (continuous), and fecal elastase deficiency status (defined as a discrete variable: fecal elastase more or less than 200 g/g), respectively, were computed by univariate or multivariate linear regression (supplementary data, published as supplemental data on The Endocrine Society's Journals Online Web site at http://jcem.endojournals.org). In the multiple regression analyses, age and the significant variables from the univariate analyses were included. All data were analyzed using Stata 8.0 (Stata Statistical Software, Stata Corp., College Station, TX).
Results
By CT, none of the patients with exocrine dysfunction displayed dilatation of the pancreatic duct, calcifications, or pseudocysts, which are frequently identified in chronic pancreatitis. Clinical characteristics are given in Table 1 .
Pancreatic volume
The global assessment by ANOVA showed significant variance for the pancreatic volume index (P Ͻ 0.00001; Fϭ 18.98, 3 df). Mean pancreatic volume index was reduced in HNF1A mutation carriers (34.5 ml/m 2 Ϯ 9.9) as well as type 1 diabetes patients (21.4 ml/m 2 Ϯ 7.4), compared with nondiabetic controls (45.7 ml/m 2 Ϯ 11.8; P ϭ 0.007 and Ͻ 0.001, respectively), whereas for type 2 diabetes patients, no significant reduction in pancreatic volume index was seen (36.9 ml/m 2 Ϯ 13.2; Fig. 1A ). Type 1 diabetes subjects had smaller pancreatic volume index, compared with HNF1A mutation carriers (P Ͻ 0.001). Further- 
Pancreatic x-ray attenuation
The global assessment by ANOVA showed significant variance for the mean pancreatic x-ray attenuation (P ϭ 0.007; Fϭ 4.37, 3 df). The mean pancreatic x-ray attenuation in HNF1A mutation carriers (81.1 Ϯ 19.4 HU) was not statistically different from nondiabetic controls (66.0 Ϯ 23.6 HU, P ϭ 0.09; Fig. 1, B and C) . Interestingly, the attenuation was significantly increased in type 1 diabetes patients (84.4 Ϯ 21.9 HU), compared with nondiabetic controls (P ϭ 0.02), whereas subjects with type 2 diabetes had attenuation similar to nondiabetic controls (60.1 Ϯ 21.4 HU). Helical CT was performed as described in Subjects and Methods. The pancreatic volume index was calculated by dividing pancreatic volume by body surface area to control for the influence of body build on pancreatic volume. *, Statistical difference (P Ͻ 0.05). A, Pancreatic volume index was reduced in HNF1A mutation carriers, compared with nondiabetic controls (P ϭ 0.02), whereas type 1 diabetes (T1D) subjects had reduced pancreatic volume index compared with HNF1A mutation carriers, type 2 diabetes (T2D) patients, and nondiabetic controls (all P Ͻ 0.001). B, For HNF1A mutation carriers, the mean pancreatic attenuation did not differ from nondiabetic controls or type 1 diabetes patients. The mean pancreatic attenuation was increased in type 1 diabetes patients, compared with nondiabetic controls (P ϭ 0.04). C, CT at the level of the pancreatic body and tail in an HNF1A mutation carrier, a patient with type 1 diabetes and fecal elastase deficiency, and a nondiabetic control. The pancreas of the type 1 diabetes subject demonstrates reduced volume and increased attenuation. No striking differences are apparent between the HNF1A mutation carrier and the control subjects. When analyzed at the group level, HNF1A mutation carriers have significantly smaller pancreatic volume and a trend toward higher mean x-ray attenuation than nondiabetic subjects. The arrows mark the position of the pancreas.
variate linear regression analyses. Adjusting for age and BMI in a multivariate regression analysis only slightly modified the association of pancreatic attenuation with diabetes status in the comparison of nondiabetic controls and HNF1A mutation carriers [P ϭ 0. 
Discussion
To our knowledge, this is the first study on pancreatic size and structure in HNF1A-MODY. We found that HNF1A as well as type 1 diabetes patients had significantly reduced pancreatic volume index, compared with nondiabetic controls. Our results for types 1 and 2 diabetes are consistent with previous reports (6, 15, 16) . Subjects with type 1 diabetes had smaller pancreatic volume index than HNF1A mutation carriers, and this reduction remained significant after adjusting for age, diabetes duration, and fecal elastase deficiency. Reduced pancreatic volume index was associated with diabetes duration in agreement with some (8) but not all (6, 7) previous studies. Reduced insulinotropic effects on the acinar cells is a possible mechanism for the reduction in pancreatic volume (10, 11) , and reports show association of small pancreatic volume with insulin use (8) or reduced insulin secretion (7). This is in line with our data because type 1 diabetes patients generally have the most pronounced endogenous insulinopenia.
Subjects with fecal elastase deficiency had a significant reduction in pancreatic volume index, in accordance with a recent report showing an association between pancreatic volume index and the exocrine pancreatic function marker serum immunoreactive trypsin (6) . Both the reduced pancreatic volume and reduced pancreatic exocrine function observed in our patients may be due to local paracrine effects of insulinopenia (10) . The more severe insulin deficiency observed in type 1 diabetes probably explains the greater pancreatic volume reduction compared with HNF1A-MODY. We cannot, however, rule out the possibility that primary exocrine disease is involved in the pancreatic volume reduction.
A recent study reported higher pancreatic fat content in type 2 diabetic compared with nondiabetic men and a negative correlation of pancreatic fat with ␤-cell function (17), whereas others found no increase in pancreatic fat in type 2 diabetes (16). Interestingly, we experienced that pancreatic x-ray attenuation adjusted for age and BMI was significantly increased in subjects with type 1 diabetes and observed the same tendency in HNF1A mutation carriers. In contrast, type 2 diabetes patients had pancreatic x-ray attenuation similar to controls. We further found that pancreatic x-ray attenuation decreased with increasing BMI, confirming previous findings of strong correlation between BMI and fat content in the pancreas (16, 18) . The observed differences between diabetes subtypes may be due to differences in insulin secretion, which has been reported to be directly associated with pancreatic fat content (18) .
Pancreatic lipomatosis is an early structural marker of pancreatic exocrine disease in CEL mutation carriers preceding development of diabetes (5) . Fatty replacement of the pancreas has also been observed in cystic fibrosis and JohanssonBlizzard syndrome, two monogenic conditions with primary affection of the exocrine pancreas and frequent development of secondary diabetes (19, 20) . We did not find any association of pancreatic x-ray attenuation with fecal elastase in HNF1A mutation carriers. This suggests a different pathophysiological mechanism for the development of pancreatic changes in HNF1A-MODY.
In conclusion, the pancreatic volume index was reduced in HNF1A-MODY, compared with nondiabetic controls, but less than in type 1 diabetes. A striking pancreatic atrophy such as in HNF1B MODY was not observed. Although HNF1A and HNF1B are closely related and interact in the same transcriptional network, HNF1A clearly has less pronounced effect on pancreas volume and structure than HNF1B (1, 2, 21) . Our data support the notion that insulinopenia is the main factor determining the reduction in pancreatic volume in HNF1A-MODY as well as in type 1 diabetes, whereas in HNF1B-MODY a developmental effect is likely to be involved. Insulinopenia probably also explains the pancreatic exocrine dysfunction associated with pancreatic volume reduction, but further studies, particularly of nondiabetic HNF1A mutation carriers, would be helpful to evaluate a possible primary role of the exocrine pancreas.
